Yazar "Yildirim, A." seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Analysis of human omentum-associated lymphoid tissue components with S-100: an immunohistochemical study(Editura Acad Romane, 2010) Yildirim, A.; Aktas, A.; Nergiz, Y.; Akkus, M.Milky spots are opaque patches in the greater omentum. They were first described by von Recklinghausen (1863) in the omentum of rabbits. In man, milky spots are relatively uniform, highly vascularized accumulations of mononuclear cells. The objective of this study was to describe in human omental lymphoid tissue components with S-100. Tissue samples (greater omentum) were collected from 14 patients operated with different reasons in our Department of General Surgery, in order to histologically present the presence of S-100 in the cells making up the milky spots in human omentum tissue. Tissue samples were cut approximately 5-8 micrometer thick with frozen-sections and stained with an indirect immunoperoxidase technique, as described previously. Then milky spots were examined by light microscopy. These data indicate that unstimulated milky spots in the human greater omentum are to a great extent just a preformed specific accumulation of primarily macrophages within the stroma of the greater omentum, secondarily B-and T-lymphocytes. In addition to these cells, we observed that a few mast and reticular cells were seen in the milky spots by S-100 reactive cross-sections of greater omentum. In the human omentum tissue that was stained with indirect immunoperoxidase method using anti S-100 monoclonal antibody, an arteriole cross-section in the center, reactive nerve cross-sections in the adjacent stroma and endogenic peroxidase reactivity in a few granulocytes in omental tissue were observed.Öğe The evaluation of cases with Factor X deficiency in Southern East of Turkey(Wiley-Blackwell, 2013) Soker, M.; Karabel, M.; Yildirim, A.; Oymak, Y.; Kelekci, S.; Karabel, D.[Abstract Not Available]Öğe Intraocular pressure during micturition in benign prostatic hyperplasia(Verduci Publisher, 2015) Sahin, A.; Yilmaz, A.; Yildirim, A.[Abstract Not Available]Öğe Risk-adapted screening in bladder cancer as a new strategy in bladder cancer is feasible using a computer-based questionnaire, Risikocheck V4.0, evaluated in an international multicentre trial(Elsevier Science Bv, 2008) Luedecke, G.; Tuerker, P.; Gueoluesoy, B.; Yildirim, A.; Aslan, G.; Mungan, A.; Battaci, S.[Abstract Not Available]Öğe Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity(Springer London Ltd, 2018) Sahin, A.; Gursel-Ozkurt, Z.; Sahin, M.; Turkcu, F. M.; Yildirim, A.; Yuksel, H.We aimed to investigate the effectivity of the 0.0625 mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625 mg dose of intravitreal bevacizumab (IVB) injection. The medical records of the patients with type 1 ROP who received IVB monotherapy were retrospectively reviewed. Demographic and clinical characteristics of the patients were recorded. The patients were classified into two groups with respect to received dose of bevacizumab as follows: group F (n = 46) (full dose of bevacizumab-0.625 mg/0.025 ml) and group L (n = 45) (low dose (one tenth) of bevacizumab-0.0625 mg/0.025 ml). Both treatment dose regimens have similar outcomes. Moreover, the mean retinal vascularization time seemed to be significantly higher in group F compared to group L, 168 +/- 65 and 97 +/- 29 days, respectively (p < 0.001). Disappearance of plus sign is observed earlier in group F (2.45 +/- 1.7 vs 3.66 +/- 2.46 days, respectively, p = 0.03). The low dose (0.0625 mg) of IVB treatment was effective as full (0.625 mg) dose in ROP treatment. Moreover, our results showed that low-dose treatment might provide faster retinal vascularization than the regular used dose. On the other hand, disappearance of the plus sign takes longer time in patients treated with low dose compared to eyes treated with full dose of IVB that should be taken into account.
